This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

This study has been completed.
Information provided by (Responsible Party):
Allergan Identifier:
First received: July 14, 2008
Last updated: December 5, 2011
Last verified: December 2011
This study will evaluate the efficacy of cyclosporine ophthalmic solution vs. other non-prescription treatments in patients with dry eye disease. Patient and physician assessments completed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.

Condition Intervention
Keratoconjunctivitis Sicca Drug: cyclosporine ophthalmic emulsion 0.05%, artificial tears

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Ocular Surface Disease Index (OSDI) Total Score at Baseline [ Time Frame: Baseline ]
    The OSDI consists of 12 questions to assess visual function, ocular symptoms and environmental triggers related to dry eye. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4 = all of the time) which is converted to a total score between 0-100. OSDI total scores of 0-12=normal (best), 13-22= mild ocular surface disease, 23-32 =moderate ocular surface disease, and 33-100=severe ocular surface disease (worst).

Enrollment: 781
Study Start Date: September 2004
Study Completion Date: August 2008
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
  • cyclosporine ophthalmic emulsion 0.05%
  • artificial tears
Drug: cyclosporine ophthalmic emulsion 0.05%, artificial tears
one drop, twice a day in each eye
Other Name: Restasis®


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients can either:

  1. be newly diagnosed or changing therapies and require, in the judgment of the treating physician, a prescription treatment
  2. have insufficiently controlled dry eye symptoms necessitating use of over-the-counter treatments

Inclusion Criteria:

  • Diagnosis of dry eye disease
  • Currently using artificial tears daily
  • Male or female of legal age of consent
  • Normal lid position and closure

Exclusion Criteria

  • Patients currently using cyclosporine ophthalmic emulsion 0.05%
  • Participation in other investigational drug or device study
  • Any current or previous topical ophthalmic or oral cyclosporine use within the last three years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00717418

United States, North Carolina
Wilson, North Carolina, United States
Sponsors and Collaborators
Study Director: Medical Director Allergan
  More Information

Responsible Party: Allergan Identifier: NCT00717418     History of Changes
Other Study ID Numbers: R.E.S.T.O.R.E.
Study First Received: July 14, 2008
Results First Received: December 5, 2011
Last Updated: December 5, 2011

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Conjunctival Diseases
Eye Diseases
Corneal Diseases
Lacrimal Apparatus Diseases
Lubricant Eye Drops
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors
Ophthalmic Solutions
Pharmaceutical Solutions processed this record on June 23, 2017